Plain-English translation of NCT06668181 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called in children and teenagers (ages 2–17) who have active juvenile arthritis, specifically enthesitis-related arthritis or psoriatic arthritis. Researchers want to understand how this medication works in children's bodies and whether it is safe and helpful for reducing joint pain and swelling.
Current arthritis treatments don't work well enough for all children with these types of juvenile arthritis. This medication is designed to work differently than other treatments, and researchers need to study how it performs specifically in children to see if it could be a better option.
You likely qualify if…
You likely don't qualify if…
Your child will receive doses of the medication by injection under the skin at home, with the dose based on their weight. You will attend study visits where the research team checks how the medication is working, takes blood samples to measure medication levels, and monitors for any side effects. The study lasts several months, and your child may continue other arthritis medications they are already taking if they have been stable.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Canada
France